Authors: Yasui H, Idogawa M, Ishida T, Imai K.
Abstract Summary
Therapeutic antibodies are transforming hematology treatment. Anti-CD20, CD19, CD38, and BCMA antibodies significantly improve survival in blood cancers, while complement inhibitors like eculizumab revolutionize rare blood disorders. Novel formats including bispecific and trifunctional antibodies show enhanced efficacy.
Why Brain? đ§
Therapeutic antibodies have transformed blood disorder treatment, significantly improving survival in cancers like leukemia and myeloma while revolutionizing care for hemophilia and rare blood diseases.
License: cc by.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
